For the Inventor, By the Inventor

Enter assignee name

Vancouver, Canada

Zymeworks Bc Inc.

USPTO Granted Patents = 18

CIPO Patents = 2

EPO Patents = 6

Trademarks = 8

Forward Citations = 0

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Mario Sanches (6 out of 18 patents)

Dunja Urosev (6 out of 12 patents)

James R Rich (6 out of 16 patents)

4. Nina E Weisser (5 out of 8 patents)

5. Surjit Bhimarao Dixit (5 out of 5 patents)

6. Stuart Daniel Barnscher (4 out of 11 patents)

7. Thomas Spreter Von Kreudenstein (4 out of 18 patents)

8. Tom Han Hsiao Hsieh (4 out of 13 patents)

9. Geoffrey C Winters (4 out of 14 patents)

10. Alexander Laurence Mandel (4 out of 12 patents)

11. Gordon Yiu Kon Ng (3 out of 15 patents)

12. Grant Raymond Wickman (3 out of 8 patents)

13. Adam Louis Corper (3 out of 9 patents)

14. Stacey A L Tom-Yew (3 out of 10 patents)

15. Eric Escobar-Cabrera (3 out of 14 patents)

18 patents: Sort by Forward Citations

1. 12540198 - Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof (2026-02-03),

2. 12435157 - Methods of using a bispecific antigen-binding construct targeting HER2 for the treatment of biliary tract cancers (2025-10-07),

3. 12433952 - Antibody-drug conjugates targeting folate receptor alpha and methods of use (2025-10-07),

4. 12357701 - Anti-HER2 biparatopic antibody-drug conjugates and methods of use (2025-07-15),

5. 12304954 - Multivalent and bispecific antibody constructs and methods of use thereof (2025-05-20),

6. 12304945 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2025-05-20),

7. 12303544 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2025-05-20),

8. 12286489 - Modified antigen binding polypeptide constructs and uses thereof (2025-04-29),

9. 12227591 - Antigen-binding constructs targeting HER2 (2025-02-18),

10. 12215166 - Bispecific antigen binding constructs targeting HER2 (2025-02-04),

11. 12157775 - Methods of using bispecific antigen-binding constructs targeting HER2 (2024-12-03),

12. 12152083 - Cytotoxic and anti-mitotic compounds, and methods of using the same (2024-11-26),

13. 12076400 - Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer (2024-09-03),

14. 12060436 - Engineered immunoglobulin heavy chain-light chain pairs and uses thereof (2024-08-13),

15. 11965036 - Bispecific antigen-binding constructs targeting HER2 (2024-04-23),

Company Overview

Zymeworks BC Inc. is a biotechnology company based in Vancouver, Canada, specializing in the development of innovative therapeutic solutions. The company focuses on creating multifunctional therapeutics, particularly in the fields of oncology and autoimmune diseases, leveraging its proprietary protein engineering platform. Zymeworks aims to address unmet medical needs through its advanced research in biologics, enhancing the efficacy and safety of treatments for patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

18 Patents

#47 in

#822 in

#34,244 in the World

Vancouver, Canada

Zymeworks Bc Inc.

Forward Citations = 0

56 inventors:

Mario Sanches (6 out of 18 patents)

Dunja Urosev (6 out of 12 patents)

James R Rich (6 out of 16 patents)

4. Nina E Weisser (5 out of 8 patents)

5. Surjit Bhimarao Dixit (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Zymeworks Bc Inc.. Retrieved from https://idiyas.com/company/zymeworks-bc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…